By Katherine Hamilton
Bayer said it received approval from the Food and Drug Administration for its drug Nubeqa, which treats patients with a certain type of prostate cancer.
The German life-sciences company said Tuesday the approval is based on positive results from a phase 3 trial. The trial results showed a 46% reduction in the risk of radiographic progression or death among patients taking Nubeqa in combination with another form of therapy.
There were 669 patients in the randomized, placebo-controlled trial, Bayer said.
Nubeqa is indicated in the U.S. for the treatment of adults with metastatic and non-metastatic castration-sensitive prostate cancer.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
June 03, 2025 19:15 ET (23:15 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.